Leading in China

Delivering patient outcomes through innovation


Imagine a world where we no longer innovate or challenge the status quo. What could that mean for technology, the arts, or business? What would that mean for healthcare, for disease management and disease awareness?

We know we must innovate to progress and develop: as human beings, organisations and societies. As the needs of patients evolve, so too must our approach to meeting them. In China, we have moved from the traditional pharmaceutical model of simply delivering medicines, to providing holistic disease management solutions that have patient needs at the very centre.

This means more than just the right medicine at the right time. It’s about the entire patient experience, from awareness, to diagnosis, treatment and beyond. In China, we collaborate with cross-sector partners including the government, industry, academia, research institutes and medical institutions, using the Internet of Things (IoT), Big Data, Artificial Intelligence (AI) and other innovative technology to meet patients’ needs.

 

We are delivering new locally developed medicines where China is leading global studies, both through in house and cooperative R&D, as well as introducing innovative solutions developed by companies both inside and outside of China. This puts us at the forefront of innovation and enables us to launch products at speed and provide holistic healthcare solutions that meet patient needs.

Leon Wang EVP International, CP China & HK


Innovation in action


Since entering China in 1993, we have invested more than $1 billion and have introduced 30 innovative medicines.

In 2017 we launched the China Commercial Innovation Centre (CCIC) in Wuxi to create an innovative healthcare ecosystem that would provide patients with holistic disease management solutions. Practically, what this means, is having access to everything the patient needs under one roof – one central place for information, care and support.

Within the Centre, we have launched eight fully-integrated disease management solutions. To date, we have solutions in respiratory, oncology, gastrointestinal, cardiovascular and metabolic diseases. Not only are we due to deliver another seven new solutions in 2019, but other markets have taken inspiration from the China Commercial Innovation Centre to develop solutions locally, with Russia looking to launch a similar IoT centre later this year.


Commitment to partnership


We recognise the power of partnerships in order to deliver truly patient-centric solutions. We partner with Governments, education providers and relevant industries to provide the holistic solutions patients need. Combining our strengths allows us to be truly innovative, become a partner of choice and accelerate product launches.

 

 

In March 2019 we signed a Memorandum of Understanding (MoU) with the Wuxi High-tech District at the Boao Forum for Asia Annual Conference to build an International Life Science Innovation Campus in conjunction with the Wuxi municipal government. This new ecosystem will provide both domestic and international start-up companies with shared resources, including laboratories, equipment and services. It will also facilitate global R&D collaboration to accelerate innovation, supporting the development and commercialisation of healthcare solutions in China.



China is a great example of how innovation can deliver real impact for patients and change the way they manage or recover from disease.

If we stop innovating, we stop improving patient outcomes. We are committed to staying ahead of the curve, working on the next wave of disruptive technology and innovation, to better serve patients in China and across the world.